UBS Downplays G7 CGM Sensor Concerns, Affirms DexCom's Inc. (DXCM) 'Buy' Rating

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated the bullish stance even as the company faces concerns over its G7 continuous glucose monitoring sensor.

The device has come under scrutiny over allegations of inaccuracies in readings that have led to hospitalization and deaths. UBS has come to its defense, with analyst Danielle Antalffy insisting that physician checks, management conversations, and surveys have yet to indicate any differences in reliability or quality.

The research firm expects the G7 continuous glucose monitoring device to continue eliciting strong demand, given the broader adoption trajectory for CGM technology.

DexCom, Inc. (NASDAQ:DXCM) develops and sells continuous glucose monitoring (CGM) systems that help people with diabetes track and manage their blood sugar levels. Their wearable sensors send real-time glucose data to a smart device, allowing users to make informed decisions about food, activity, and medication, and to live more freely by reducing the need for frequent finger pricks.

While we acknowledge the potential of DXCM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 14 Best FMCG Stocks to Invest In and 13 Best Cryptocurrency Stocks to Buy According to Wall Street Analysts

Disclosure: None. This article is originally published at Insider Monkey.